TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07314294: A Randomized, Open-label, Phase II Study of EMB-01 in Patients With Recurrent/Metastatic Colorectal Cancer

Sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 54 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07314294 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07314294 Rescue Dossier →